THE CYP2D6 'ENHANCER' SNP: LONG-RANGE LINKAGE ANALYSIS AND IMPACT ON ACTIVITY IN HUMAN LIVER TISSUE

被引：0
|
作者：
Gaedigk, Andrea [1 ]
Boone, Erin C. [1 ]
Dinh, Jean C. [1 ]
Gaedigk, Roger [1 ]
Lata, Ryan F. [1 ]
Pearce, Robin E. [1 ]
Wang, Wendy Y. [1 ]
Miller, Neil A. [1 ]
Staggs, Vincent S. [1 ]
Leeder, J. Steven [1 ]
机构：
[1] Childrens Mercy Kansas City, Kansas City, MO USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2020年 / 35卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P191
引用
收藏
页码：S80 / S81
页数：3
相关论文
共 50 条
  • [1] LONG-RANGE LINKAGE ANALYSIS TO ESTABLISH CYP2D6 'ENHANCER' SINGLE NUCLEOTIDE POLYMORPHISM (SNP) HAPLOTYPE.
    Gaedigk, A.
    Boone, E.
    Gaedigk, R.
    Wang, W.
    Miller, N.
    Leeder, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S86 - S86
  • [2] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [3] THE 'ENHANCER' SNP DOES NOT EXPLAIN VARIABILITY OF CYP2D6 ACTIVITY IN VIVO.
    Boone, E. C.
    Staggs, V. T.
    Pearce, R. E.
    Lata, R. F.
    Gaedigk, R.
    Jaime, L. K. Montane
    Cherner, M.
    Berard, A.
    Fridley, B. L.
    Dinh, J. C.
    Miller, N. A.
    Leeder, J.
    Gaedigk, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S57 - S57
  • [4] Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity
    Wang, Danxin
    Poi, Ming J.
    Sun, Xiaochun
    Gaedigk, Andrea
    Leeder, J. Steven
    Sadee, Wolfgang
    HUMAN MOLECULAR GENETICS, 2014, 23 (01) : 268 - 278
  • [5] Human liver CYP2D6 genotype, full-length mRNA, and activity, assessed with a novel CYP2D6 substrate
    Bodor, M
    McConnachie, L
    Kowdley, K
    Levy, A
    Tun, B
    Thummel, K
    Phillips, B
    Bajpai, M
    Chi, V
    Esmay, JD
    Shen, DD
    Ho, RJY
    DRUG METABOLISM REVIEWS, 2004, 36 : 113 - 113
  • [6] EXPRESSION OF CYP2D6 IN DEVELOPING HUMAN LIVER
    TRELUYER, JM
    JACQZAIGRAIN, E
    ALVAREZ, F
    CRESTEIL, T
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1991, 202 (02): : 583 - 588
  • [7] Analysis of CYP2D6 expression in human lung: Implications for the association between CYP2D6 activity and susceptibility to lung cancer
    Kivisto, KT
    Griese, KU
    Stuven, T
    Fritz, P
    Friedel, G
    Kroemer, HK
    Zanger, UM
    PHARMACOGENETICS, 1997, 7 (04): : 295 - 302
  • [8] Functional characterization of CYP2D6 enhancer polymorphisms
    Wang, Danxin
    Papp, Audrey C.
    Sun, Xiaochun
    HUMAN MOLECULAR GENETICS, 2015, 24 (06) : 1556 - 1562
  • [9] C-1584G polymorphism is not the very SNP causing increased CYP2D6 activity of CYP2D6*41.
    Lee, S
    Jeong, H
    Yea, S
    Shin, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P67 - P67
  • [10] Interactions of amphetamine analogs with human liver CYP2D6
    Wu, DF
    Otton, SV
    Inaba, T
    Kalow, W
    Sellers, EM
    BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) : 1605 - 1612
12345